Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allogene Therapeutics Inc ALLO

Healthcare Biotechnology
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a... see more

Recent & Breaking News (NDAQ:ALLO)

Allogene Therapeutics Announces Q2 Investor Conference Participation

GlobeNewswire April 9, 2024

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

GlobeNewswire March 14, 2024

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

GlobeNewswire March 12, 2024

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

GlobeNewswire March 5, 2024

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

GlobeNewswire February 28, 2024

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

GlobeNewswire February 16, 2024

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire January 16, 2024

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

GlobeNewswire January 4, 2024

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

GlobeNewswire January 4, 2024

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

GlobeNewswire December 9, 2023

Allogene Therapeutics Announces Participation in December Investor Conference

GlobeNewswire December 1, 2023

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire November 3, 2023

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak(TM) and Dagger(TM) Technologies at the Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire November 3, 2023

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

GlobeNewswire November 2, 2023

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

GlobeNewswire November 2, 2023

Allogene Therapeutics Announces Participation in November Investor Conferences

GlobeNewswire October 30, 2023

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

GlobeNewswire October 26, 2023

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

GlobeNewswire October 16, 2023

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T(TM) Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire September 27, 2023